Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Next Previous
Trial Profile

Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 22 May 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2027.
  • 22 May 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
  • 10 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top